Applicability of nuclear androgen receptor quantification to human prostatic adenocarcinoma.
It has been proposed that concentrations of nuclear androgen receptor may be predictive of tumor hormone dependence in cases of advanced human prostatic cancer. We have investigated the ability of this receptor population to reflect patient prognosis during endocrine therapy in 12 cases of stage D disease. KCl-extractable, nuclear matrix-bound and total nuclear androgen receptor concentrations showed a significant positive correlation with duration of patient survival (p less than 0.05) while cytosolic and total cellular androgen receptor concentrations were not significantly correlated with survival. However, use of selected threshold concentrations of receptors revealed that only cytosolic, nuclear KCl-extractable and total cellular receptors could significantly differentiate long-term and short-term survivors. Even given the small number of patients studied, the potential use of this androgen receptor assay as an index of both tumor hormone-dependence and patient prognosis was evident. Therefore, in order to make these androgen receptor assays more applicable, we attempted to simplify the methods for use on readily available tissues. Similar amounts of nuclear androgen binding were observed in crude and purified nuclear pellets, in nuclei treated with DNase and KCl in differing orders or in nuclei from tissue homogenized using glass or Polytron homogenization procedures. More importantly, nuclear androgen receptor concentrations in specimens of prostatic cancer or benign hyperplasia taken by needle biopsy or transurethral resection involving electrocautery did not differ from those of parallel specimens taken by Thompson cold punch. Simplified nuclear androgen receptor assays of needle biopsy or electrocautery specimens are accurate and should prove clinically applicable.
D000230:Adenocarcinoma / Q000032:analysis* / Q000401:mortality / Q000628:therapy; D001706:Biopsy; D004054:Diethylstilbestrol / Q000627:therapeutic use; D004564:Electrocoagulation; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011379:Prognosis; D011467:Prostate / Q000473:pathology; D011471:Prostatic Neoplasms / Q000032:analysis* / Q000401:mortality / Q000628:therapy; D011944:Receptors, Androgen / Q000032:analysis*; D013048:Specimen Handling / Q000379:methods; D013997:Time Factors
D011944:Receptors, Androgen; D004054:Diethylstilbestrol